Gainers

• iSpecimen (NASDAQ:ISPC) shares rose 21.1% to $0.24 during Monday's after-market session. The company's market cap stands at $2.7 million.
• Cue Biopharma (NASDAQ:CUE) shares increased by 19.71% to $0.37. The company's market cap stands at $25.8 million. As per the press release, Q4 earnings came out today.
• Akari Therapeutics (NASDAQ:AKTX) stock moved upwards by 16.42% to $0.24. The market value of their outstanding shares is at $8.1 million.
• DocGo (NASDAQ:DCGO) shares increased by 12.74% to $0.73. The market value of their outstanding shares is at $64.2 million. As per the news, the Q4 earnings report came out today.
• WORK Medical Tech Gr (NASDAQ:WOK) shares moved upwards by 6.72% to $1.27.
• Assertio Holdings (NASDAQ:ASRT) stock rose 6.1% to $12.49. The company's market cap stands at $74.0 million. The company's, Q4 earnings came out today.

Losers

• LENSAR (NASDAQ:LNSR) stock decreased by 22.4% to $7.96 during Monday's after-market session. The market value of their outstanding shares is at $117.5 million.
• Nasus Pharma (AMEX:NSRX) shares decreased by 8.39% to $2.84. The company's market cap stands at $58.5 million.
• Inspira Technologies Oxy (NASDAQ:IINN) stock decreased by 7.77% to $0.55. The market value of their outstanding shares is at $24.1 million.
• Lunai Bioworks (NASDAQ:LNAI) stock declined by 7.41% to $0.2. The market value of their outstanding shares is at $4.4 million.
• Azitra (AMEX:AZTR) stock fell 6.49% to $0.15. The company's market cap stands at $1.8 million.
• Skye Bioscience (NASDAQ:SKYE) shares declined by 6.39% to $0.67. The market value of their outstanding shares is at $21.1 million. The company's, Q4 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.